Temporal Trends in Red Blood Transfusion Among US Dialysis Patients, 1992-2005

American Journal of Kidney Diseases

Volumn 52, Issue 6, 2008, Pages 1115-1121

  Ibrahim, Hassan N ^a,b   Ishani, Areef ^a,b   Foley, Robert N ^a   Guo, Haifeng ^a   Liu, Jiannong ^a   Collins, Allan J ^a,b  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Erythropoiesis stimulating agents; hemodialysis; transfusions

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ACCURACY; ADULT; AGED; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOME HEALTH AGENCY; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INSURANCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; NURSING HOME; OUTCOME ASSESSMENT; OUTPATIENT; PERIPHERAL VASCULAR DISEASE; POISSON DISTRIBUTION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TRANSIENT ISCHEMIC ATTACK; UNITED STATES;

ADULT; AGED; COHORT STUDIES; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 56049114196     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.07.022     Document Type: Article

References (15)

1. Goodnough L.T., Monk T.G., and Andriole G.L. Erythropoietin therapy. N Engl J Med 336 (1997) 933-938
2. Higgins M.R., Grace M., Ulan R.A., et al. Anemia in hemodialysis patients. Arch Intern Med 137 (1977) 172-176
3. Jones M., Ibels L., Schenkel B., et al. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis. Kidney Int 65 (2004) 757-767
4. Ross S.D., Fahrbach K., Frame D., et al. The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review. Clin Ther 25 (2003) 1786-1805
5. Delano B.G. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 14 (1989) 14-18
6. Beusterien K.M., Nissenson A.R., Port F.K., et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 7 (1996) 763-773
7. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
8. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
9. Fishbane S., and Nissenson A.R. The new FDA label for erythropoietin treatment: How does it affect hemoglobin target?. Kidney Int 72 (2007) 806-813
10. Amgen. Aranesp. [package insert] (2007), Amgen, Thousand Oaks, CA
11. Goodnough L.T., Strasburg D., Riddell J., et al. Has recombinant human erythropoietin therapy minimized red-cell transfusions in hemodialysis patients?. Clin Nephrol 41 (1994) 303-307
12. US Renal Data System. USRDS 1995 Annual Data Report (1995), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
13. Besarbe A., Bolton K., Browne J., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1989) 584-590
14. Hakim R.M., Stivelman J.C., and Schulman G. Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis 10 (1987) 293-299
15. Cardarelli F., Pascual M., Tolkoff-Rubin N., et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int 18 (2005) 532-540